This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Neirotti, M. Articles by Pernigotti, L. Search for Related Content PubMed PubMed Citation Articles by Neirotti, M. Articles by Pernigotti, L. Social Bookmarking                         What's this?

Functional Vascular Disorders: Treatment with Pentoxifylline

Department of Gerontology and Geriatrics, University of Thrin, Turin, Italy

Flavia Flavia Longo

Department of Gerontology and Geriatrics, University of Thrin, Turin, Italy

Mario Molaschi

Department of Gerontology and Geriatrics, University of Thrin, Turin, Italy

Carmine Macchione

Department of Gerontology and Geriatrics, University of Thrin, Turin, Italy

Luigi Pernigotti

Department of Gerontology and Geriatrics, University of Thrin, Turin, Italy

A group of 11 female patients (mean age 33.7±8 years) with a clearly proven primary Raynaud's syndrome of up to five years' duration were subjected to a two-month oral treatment with 3 x 400 mg pentoxifylline per day. The following parameters were studied without and with exposure to cold conditions: hemody namics (finger photoplethysmography), red cell deformability (filtration test), various clotting variables (prothrombin activity, antithrombin III, plasma fi brinogen, partial thromboplastin time, thrombin time, thrombelastogram), and clinical symptomatology.

After treatment 7 of the 11 patients showed a distinct improvement of pe ripheral blood flow and of symptoms (decrease or removal of asphyxia attacks, pain, color change) under basal conditions, as well as after exposure to cold. Red cell filtration was significantly (p < 0.05) improved, increasing by 35% un der normal conditions and by 30% after exposure to cold. Positive changes were also found in respect to antithrombin III (increase) and plasma fibrinogen (de crease). The thrombelastogram was unchanged.

Clinical and instrumental improvements were probably ascribable to better microcirculatory flow due to increased red cell deformability, reduced viscosity, and decreased fibrinogen, all capable of influencing in various degrees the blood flow at the microcirculatory level.

Angiology, Vol. 38, No. 8, 575-580 (1987)
DOI: 10.1177/000331978703800801


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. Belch Raynaud's phenomenon Cardiovasc Res, January 1, 1997; 33(1): 25 - 30. [Full Text] [PDF]

				E. Arosio, G. Montesi, M. Zannoni, F. Paluani, and A. Lechi Comparative Efficacy of Ketanserin and Pentoxiphylline in Treatment of Raynaud's Phenomenon Angiology, July 1, 1989; 40(7): 633 - 638. [Abstract] [PDF]

				T. Roeren, R. F. LeVeen, and L. Nugent Photoplethysmographic Documentation of Improved Microcirculation After Pentoxifylline Therapy Angiology, January 1, 1988; 39(11): 929 - 933. [Abstract] [PDF]